Compare Medtronic PLC (MDT) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Oxford Lane Capital Corp — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Oxford Lane Capital Corp trades at $8.58 (market cap $835.71M). The key difference: Medtronic PLC is far larger — about 134.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Oxford Lane Capital Corp for 50 Days on average.
| MDT | OXLC | |
|---|---|---|
Market Cap | $112.24B | $835.71M |
Volume | 105,663,236 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $105.35 | $16.74 |
52-Week Low | $73.75 | $8.15 |
Typical Hold Time | 63 Days | 50 Days |
Enterprise Value | $131.58B | $1.23B |
Dividend Yield | 3.28% | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
OXLC trades at $8.56, up 1.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows a low P/B of 0.81 and pays a consistent $0.20 monthly dividend. However, recent earnings have significantly missed expectations, with a Q1 2026 loss of -$6.23 per share, and 2026 revenue and net profit trends are deeply negative, raising sustainability concerns.
The outlook is highly speculative. The deep discount to book value and high dividend yield present a potential value opportunity for income-focused investors, but this is offset by severe profitability erosion, negative cash flow from operations, and analyst skepticism. Key risks include the company's ability to stabilize its net asset value and fund its dividend without further capital erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
